VOR
Vor Biopharma Inc. · Healthcare
Insiders sold $49.4M of Vor Biopharma Inc. in the last 12 months and bought none
VOR over the last year
VOR after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
10 insider filings since 2021, newest first
Ra Capital Management, L.P. · Director and 10% owner
Ra Capital Management, L.P. · Director and 10% owner
Ra Capital Management, L.P. · Director and 10% owner
Ra Capital Management, L.P. · Director and 10% owner
Ra Capital Management, L.P. · Director and 10% owner
5Am Ventures Vi, L.P. · 10% owner
Kush Parmar · Director and 10% owner
Ra Capital Management, L.P. · Director and 10% owner
5Am Ventures Vi, L.P. · 10% owner
Kush Parmar · Director and 10% owner
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.